Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients

Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated acute myeloid leukemia (AML) patients. However, upfront resistance as well as relapse following initial response demonstrate the need for a deeper understanding of resistance mechanisms. In the present s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Autores principales: Pei, Shanshan, Pollyea, Daniel A., Gustafson, Annika, Stevens, Brett M., Minhajuddin, Mohammad, Fu, Rui, Riemondy, Kent A., Gillen, Austin E., Sheridan, Ryan M., Kim, Jihye, Costello, James C., Amaya, Maria L., Inguva, Anagha, Winters, Amanda, Ye, Haobin, Krug, Anna, Jones, Courtney L., Adane, Biniam, Khan, Nabilah, Ponder, Jessica, Schowinsky, Jeffrey, Abbott, Diana, Hammes, Andrew, Myers, Jason R., Ashton, John M., Nemkov, Travis, D’Alessandro, Angelo, Gutman, Jonathan A., Ramsey, Haley E., Savona, Michael R., Smith, Clayton A., Jordan, Craig T.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124979/
https://ncbi.nlm.nih.gov/pubmed/31974170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0710
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares